ERBB2 and aneurysmal bone cyst: Based on the promising antitumor activity, two phase 3 trials testing DS-8201a versus T‐DM1 (clinicaltrials.gov identifier: NCT03529110) and versus physicians’ choice (NCT03523585) are currently enrolling pretreated HER2-positive ABC patients.